From: BRCA2 carriers with male breast cancer show elevated tumour methylation
 | GSTP1 | RASSF1A | MAL | RUNX3 | RARβ | APC | FOXC1 | AMI (median) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hypermethylation | + | - | + | - | + | - | + | - | + | - | + | - | + | - | > | < |
Age (years) | Â | Â | Â | Â | 59.1 | 65.7 | Â | Â | 67.2 | 60.9 | 69.1 | 60.4 | Â | Â | Â | Â |
p-value | Â | Â | Â | Â | Â | 0.04 | Â | Â | Â | 0.07 | Â | 0.01 | Â | Â | Â | Â |
Tumour size (mm) | Â | Â | Â | Â | Â | Â | Â | Â | 22.3 | 16.5 | 21.4 | 17.1 | Â | Â | 20.8 | 15.8 |
p-value | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.01 | Â | 0.08 | Â | Â | Â | 0.02 |
IC-NST Histology | Â | Â | Â | Â | Â | Â | 94% | 69% | Â | Â | Â | Â | Â | Â | Â | Â |
p-value | Â | Â | Â | Â | Â | Â | Â | 0.046 | Â | Â | Â | Â | Â | Â | Â | Â |
Grade 3 | 51% | 18% | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
p-value | Â | 0.09 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Paget’s Disease |  |  |  |  |  |  |  |  | 31% | 8% |  |  |  |  |  |  |
p-value | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.04 | Â | Â | Â | Â | Â | Â |
DCIS present | Â | Â | 33% | 6% | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
p-value | Â | Â | Â | 0.02 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Lymphovascular invasion | 49% | 18% | Â | Â | Â | Â | Â | Â | Â | Â | 20% | 51% | 53% | 40% | Â | Â |
p-value | Â | 0.09 | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.07 | Â | 0.09 | Â | Â |
Perineural invasion | Â | Â | Â | Â | Â | Â | Â | Â | 63% | 36% | Â | Â | Â | Â | Â | Â |
p-value | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.07 | Â | Â | Â | Â | Â | Â |
Node positive | Â | Â | 52% | 24% | Â | Â | Â | Â | 62% | 34% | Â | Â | Â | Â | Â | Â |
p-value | Â | Â | Â | 0.08 | Â | Â | Â | Â | Â | 0.07 | Â | Â | Â | Â | Â | Â |
HER2 positive | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 13% | 0 |
p-value | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.11 |